|Study Type:||Phase I|
|Stage:||Follow up complete|
|Study Start Date:||NA|
|Study Made Public:||NA|
A Phase 1 trial to evaluate the safety, tolerability, and immunogenicity of a prime-boost regimen of HIV-1 nef/tat/vif, env pDNA vaccine delivered intramuscularly with electroporation and HIV-1 rVSV envC vaccine in healthy HIV-uninfected adult participants
HVTN 112 is a Phase I clinical trial to evaluate the safety and immunogenicity of a prime/boost regimen using HIV-1 nef/tat/vif, env pDNA via electroporation and HIV-1 rVSV envC.
Sign in to see full information about this study and to download study data.